Clinical Trial

Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy of BGB-11417 in participants with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2022-07-27; most recent amendment 2026-03-02.
Status change: Recruiting → Active, Not Recruiting 2024-10-28
Status change: Not Yet Recruiting → Recruiting 2022-11-14
Trial Details
NCT Number NCT05479994
Lead Sponsor BeiGene
Conditions Leukemia, Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma, Relapsed Chronic Lymphocytic Leukemia
Enrollment 100 participants
Start Date 2022-10-25
Primary Completion 2025-01-24 (estimated)
Study Completion 2027-08-25 (estimated)
Updated on ClinicalTrials.gov 2026-03-04